D.E. Shaw & Co
MIRM icon

D.E. Shaw & Co’s Mirum Pharmaceuticals MIRM Stock Holding History

D.E. Shaw & Co’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Sell
167,489
-780,672
-82% -$73.4M 0.01% 1317
2025
Q4 		$74.9M Buy
948,161
+24,652
+3% +$1.77M 0.04% 521
2025
Q3 		$67.7M Buy
923,509
+368,552
+66% +$23.4M 0.04% 520
2025
Q2 		$28.2M Buy
554,957
+11,680
+2% +$520K 0.02% 838
2025
Q1 		$24.5M Buy
543,277
+385,925
+245% +$18.2M 0.02% 824
2024
Q4 		$6.51M Buy
+157,352
New +$6.56M ﹤0.01% 1777
2024
Q1 		– Sell
-22,178
Closed -$655K – 4584
2023
Q4 		$655K Sell
22,178
-1,146
-5% -$34.7K ﹤0.01% 3387
2023
Q3 		$737K Buy
+23,324
New +$639K ﹤0.01% 3243
2022
Q4 		– Sell
-36,145
Closed -$759K – 5001
2022
Q3 		$759K Buy
36,145
+11,309
+46% +$272K ﹤0.01% 3782
2022
Q2 		$483K Buy
+24,836
New +$586K ﹤0.01% 4108
2020
Q3 		– Sell
-10,581
Closed -$206K – 4026
2020
Q2 		$206K Buy
+10,581
New +$177K ﹤0.01% 3765

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

D.E. Shaw & Co's MIRM Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Mirum Pharmaceuticals (MIRM) stake by 82% in Q1 2026, selling an estimated $73.4M and leaving 167,489 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1317.

D.E. Shaw & Co first reported a position in MIRM in Q2 2020 and has held it in 11 quarters since. The position peaked at $74.9M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • D.E. Shaw & Co held 167,489 shares of Mirum Pharmaceuticals worth $15.5M as of Q1 2026.
  • D.E. Shaw & Co sold 780,672 Mirum Pharmaceuticals shares in Q1 2026, an estimated $73.4M.
  • Mirum Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1317 holding.
  • D.E. Shaw & Co first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
  • D.E. Shaw & Co's Mirum Pharmaceuticals position peaked at $74.9M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.